December 20, 2024 11:08 AM EST
Financing
Startups

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Kyle LaHucik

Senior Reporter

Sofinno­va In­vest­ments, one of the longest-stand­ing biotech in­vest­ment firms, has pen­ciled in plans for a new $550 mil­lion fund, End­points News has learned.

The Men­lo …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ap­plied Ther­a­peu­tics CEO steps down af­ter rare dis­ease drug re­jec­tion

Dai­ichi Sankyo finds suc­ces­sor to late R&D ex­ec; Ver­sant, No­var­tis' kid­ney biotech poach­es Sana CBO

Aa­di starts from scratch as it sells as­sets, li­cens­es AD­Cs and rais­es new funds

A service from the Financial Times